Discover and optimize drugs for inflammatory diseases. Discover and optimize drugs for infectious diseases. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.
Clearly below the class average.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
Growth: Sales growth trails the sector average.
Business Quality: Profit power and business quality trail similar companies in the sector.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
The stock trades 18% below its peak. The market has trimmed its expectations for the company.
Our checks did not surface a specific strength to highlight here.
A loss of $390.0M against $0 in annual sales.
At the current pace of spending, the cash lasts about 1.6 years. After that, the company needs to find new money.
On our five-subject report card, ABVX sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: ABVX is a high-risk stock — not yet profitable, and its future rides on its product catching on.
Analysts’ average target sits above today’s price, yet the valuation grade (49/100) says the stock isn’t cheap.
Not covered, because the filings we hold do not carry it: the revenue breakdown.